Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LB-02
- Development stage
- Preclinical
- Lead developer
- LexBio Therapeutics
- Modality
- Small Molecules
01
Overview
LB-02 is a small molecule therapeutic candidate currently in the IND-enabling phase of development for the treatment of solid tumors. Developed by LexBio Therapeutics, the program is positioned as a "best-in-class" asset, implying it targets a validated oncogenic pathway with the potential for improved pharmacological properties over existing agents. LexBio is a biotechnology company focused on discovering and developing next-generation small molecule drugs for cancer and autoimmune diseases. As of late 2024, the specific biological target and mechanism of action for LB-02 have not been publicly disclosed by the sponsor.
02
Targets
Coagulation Factor IXaF10 (Factor Xa)
Beyond the preview
Go deeper on LB-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LB-02.